Free Trial

Can-Fite BioPharma (CANF) SEC Filings & 10K Form

Can-Fite BioPharma logo
$1.12 +0.09 (+8.17%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$1.14 +0.01 (+0.89%)
As of 05/2/2025 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Can-Fite BioPharma SEC Filings

DateFilerForm TypeView
04/23/2025
3:30 PM
Can-Fite BioPharma (Subject)
Orca Capital AG (Filed by)
Form SCHEDULE 13G/A
04/17/2025
11:15 PM
Can-Fite BioPharma (Filer)
Form EFFECT
04/17/2025
8:16 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
3:30 PM
Can-Fite BioPharma (Subject)
Orca Capital AG (Filed by)
Form SCHEDULE 13G
04/15/2025
11:35 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2025
11:37 AM
Can-Fite BioPharma (Filer)
Form 424B5
04/14/2025
3:15 PM
Can-Fite BioPharma (Filer)
Form POS AM
04/14/2025
7:35 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/14/2025
7:00 AM
Can-Fite BioPharma (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
04/14/2025
7:05 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/24/2025
8:01 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2025
8:45 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/19/2025
8:02 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/18/2025
7:32 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/03/2025
5:04 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/18/2025
6:04 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/14/2025
4:33 PM
ARMISTICE CAPITAL, LLC (Filed by)
Can-Fite BioPharma (Subject)
Form SCHEDULE 13G/A
02/05/2025
6:02 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/27/2025
6:03 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/30/2024
6:01 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/04/2024
6:05 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/04/2024
6:09 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/18/2024
8:23 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/09/2024
6:03 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/24/2024
6:05 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/16/2024
6:07 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/08/2024
11:15 PM
Can-Fite BioPharma (Filer)
Form EFFECT
09/06/2024
3:30 PM
Can-Fite BioPharma (Filer)
Form 424B3
09/05/2024
11:15 PM
Can-Fite BioPharma (Filer)
Form EFFECT
08/30/2024
3:18 PM
Can-Fite BioPharma (Filer)
Form F-3
Registration statement for securities of certain foreign private issuers  
08/30/2024
3:18 PM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/29/2024
7:46 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/12/2024
5:45 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/09/2024
5:07 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2024
6:03 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/11/2024
6:05 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/03/2024
12:15 PM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/01/2024
6:05 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2024
6:02 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2024
3:15 PM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2024
6:04 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Elon Musk is all in on these robots … (Ad)

Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.

I'll tell you more about the $7 company Huang and Nvidia joined forces with to make it happen.
06/10/2024
6:05 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/05/2024
6:03 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/29/2024
6:05 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/22/2024
3:15 PM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2024
6:03 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/09/2024
6:03 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2024
6:11 AM
Can-Fite BioPharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NYSE:CANF) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners